Contract facts
NONECONSULTATION AND PEER REVIEW FOR THE DIVISION OF RISK ASSESSMENT AND PRIORITIZATION is a federal NONE award for Fda Office Of Acq Grant Svcs held by Versar, Inc. Estimated value $694K ($694K obligated). Current period of performance ends Jul 12, 2027. Last award drew 2 bidders. Place of performance: SILVER SPRING MD.
CONSULTATION AND PEER REVIEW FOR THE DIVISION OF RISK ASSESSMENT AND PRIORITIZATION
Recompete timing
PublicCurrent PoP ends Jul 12, 2027 (325 days remaining). Agencies typically plan 12–18 months ahead — at 10.7 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordVersar, Inc — $45.8M obligated across 82 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).
Related awards
Same incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75F40126C00062?
75F40126C00062 (Consultation and PEER REVIEW for the) is a Fda Office Of Acq Grant Svcs award with a potential value of $694K, currently held by Versar, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75F40126C00062?
Fda Office Of Acq Grant Svcs awarded 75F40126C00062 to Versar, Inc (potential $694K).
Who is the incumbent on 75F40126C00062?
Versar, Inc is the incumbent with $45.8M across 82 related awards in SCOUT’s public footprint. The current period of performance ends Jul 12, 2027.
When does Versar, Inc’s 75F40126C00062 come up for recompete?
SCOUT tracks a period-of-performance end of Jul 12, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.